In 1997, the U.S. conducted only 5 percent of its clinical studies outside of the U.S. and Western Europe, according to a study conducted by Tufts Center for Drug Development.
By 2007, that number had climbed to 29 percent.
Due to the multinational business of major drug companies, and how Americans fit in as U.S.-based employees and stockholders of GSK, as well as consumers of drugs that will be available in the U.S. market, there are global ramifications of clinical testing being conducted around the world.
The lion's share of drug studies has gone to regions with "emerging markets": Eastern Europe and Central Europe, Latin America, and south and Southeast Asia.
When it comes to "Protocol Compas" specifically, Dr. Ana Maria Marchesse of Eva Peron Children's Hospital is one of several Argentinean doctors who is highly critical of the study's methodology. She heads up the Health Professionals' Labor Association, a group of local doctors who alerted La Federacion de Profesionals de la Salud de la Republica Argentina (the Argentinean FDA) of their concerns about possible wrongdoing.
"It's impossible to say whether the 12 babies' deaths are due to the Synflorix vaccine or not, because half of the [total number of] children were given a placebo," the energetic pediatrician told ABCNews.com through a translator. "But the way the study has been conducted is reprehensible."
More
1 comment:
It costs too much to not kill children. - GSK
Post a Comment